5 Best Stocks to Buy in a Rising Market According to Wall Street Analysts

3. Summit Therapeutics (NASDAQ:SMMT)

Stock Upside Potential: 42.05%

Year To Date Gain: 26.03%

Number of Hedge Fund Holders: 25

Summit Therapeutics (NASDAQ:SMMT) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 21, analysts at Stifel reiterated a Buy rating on Summit Therapeutics (NASDAQ:SMMT) and a $45 price target.

The positive stance comes on the heels of Akeso announcing plans to disclose HARMONi-6 interim Overall Survival readout at ASCO 2026. The disclosure is to optimize the setup better than when HARMONi-2 interim OS was disclosed last year as a result of an NMPA approval.

Unlike Harmoni 2, Harmoni-6 features 33% larger sample size and all-squamous histology. The study provides a first look at an emerging OS from an ivonescimab Phase 3 trial randomized against anti-PD-1 tislelizumab. Last year, HARMONi-2 analyzed ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Akeso is seeking label expansion for Ivonescimab in China, following an interim analysis requested by Chinese health authorities that showed a clinically meaningful positive trend favoring Ivonescimab over Pembrolizumab in PD-L1.

Summit Therapeutics (NASDAQ:SMMT) is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies to treat serious, unmet medical needs. Their primary focus is the development and commercialization of ivonescimab, a potential first-in-class bispecific antibody targeting PD-1 and VEGF for the treatment of non-small cell lung cancer (NSCLC).